Therapeutic Testing
Therapeutic Testing - Related Videos
07:10
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
0 Views •
Cited by 17 •
2011
A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described. The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.
01:13
Therapeutic Index
0 Views •
2025
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
17:16
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
0 Views •
Cited by 4 •
2010
Bioimaging methods used to assess cell biodistribution of nanoparticles are applicable for therapeutic and diagnostic monitoring of nanoformulated compounds. The methods described herein are sensitive and specific when assessed by histological coregistration. The methodologies provide a translational pathway from rodent to human applications.
07:47
Anxiety Testing
0 Views •
2023
Anxiety is a commonly observed behavioral disorder that stems from fear. It is described as increased restlessness, or unpleasant feelings of fear over anticipated events. Experimenters often use rodent models to better understand anxiety disorders in humans. They use different paradigms, like exposing rodents to bright spaces or loud sounds, which are known to induce fear. These tests combined with other interventions such as surgery or drug-administration may assist researchers in pinpointing...
11:08
Tests on Wood
0 Views •
2023
Source: Roberto Leon, Department of Civil and Environmental Engineering, Virginia Tech, Blacksburg, VA Wood is a ubiquitous material that has been used in construction from the earliest times. Wood is a renewable, sustainable material with great aesthetic value. Today, there are probably more buildings constructed with wood than any other structural material. Many of these buildings are singlefamily residences, but many larger apartment buildings, as well as commercial and industrial buildings,...
FAQs
Therapeutic testing separates three decision criteria: safety, biological activity, and potential clinical benefit. A candidate may influence a neural target or disease-related process yet fail because of toxicity or limited symptom improvement. Assessing these criteria together prevents biological effects alone from being treated as evidence that an intervention is ready for clinical use.
Pharmacokinetic and dose-response studies help connect an intervention’s exposure or dosing conditions with its observed effects. In neuroscience, that relationship can be examined alongside cellular, behavioral, or symptom-level findings, allowing investigators to judge whether changes are consistent across measures and to identify treatment limitations before or during controlled clinical evaluation.
Using complementary stages reduces the risk of relying on a single experimental perspective. Cellular assays can contribute evidence about neural or synaptic effects, animal models can add behavioral findings, and controlled clinical trials can evaluate disease-related symptoms in people. Together, these results provide a broader basis for deciding whether a candidate should advance.
A typical evaluation moves from early cellular assays and animal models to pharmacokinetic, dose-response, and biomarker studies, followed by controlled clinical trials when the evidence supports progression. At each stage, investigators examine biological activity, safety, and relevant outcomes. Results from one stage help determine whether the candidate advances, is refined, or shows limitations.
Neuroscience-focused testing can track effects at several linked levels: neural circuits, synaptic function, behavior, biomarkers, and disease-related symptoms. This layered view helps researchers determine whether a treatment’s biological activity corresponds with meaningful functional or clinical change. It also helps expose cases in which an intervention produces measurable neural effects without sufficient symptom improvement.
Researchers apply this framework to candidate drugs, biologics, devices, and behavioral interventions for neurological and psychiatric disorders. The choice of intervention does not replace staged evaluation; each candidate still requires evidence about safety, activity, and potential benefit. Controlled clinical trials provide the context for judging whether earlier findings translate into clinically relevant outcomes.